A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule

Curr Top Med Chem. 2019;19(25):2318-2333. doi: 10.2174/1568026619666191019111528.

Abstract

The enzyme L-DOPA decarboxylase (DDC), also called aromatic-L-amino-acid decarboxylase, catalyzes the biosynthesis of dopamine, serotonin, and trace amines. Its deficiency or perturbations in expression result in severe motor dysfunction or a range of neurodegenerative and psychiatric disorders. A DDC substrate, L-DOPA, combined with an inhibitor of the enzyme is still the most effective treatment for symptoms of Parkinson's disease. In this review, we provide an update regarding the structures, functions, and inhibitors of DDC, particularly with regards to the treatment of Parkinson's disease. This information will provide insight into the pharmacological treatment of Parkinson's disease.

Keywords: Aromatic-L-amino-acid decarboxylase; Biosynthesis; Enzyme; Inhibitor; L-DOPA decarboxylase; Parkinson’s disease..

Publication types

  • Review

MeSH terms

  • Animals
  • Aromatic-L-Amino-Acid Decarboxylases / metabolism*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Molecular Structure
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / enzymology
  • Parkinson Disease / metabolism

Substances

  • Enzyme Inhibitors
  • Neuroprotective Agents
  • Aromatic-L-Amino-Acid Decarboxylases
  • DDC protein, human